Cartalax (AED): identity, kidney studies and claim limits
Cartalax is indexed by the US National Library of Medicine under alanyl–glutamyl–aspartic acid, also called AED or T-31. The directly identifiable primary studies reviewed here concern kidney cultures and rat kidney injury. They do not substantiate a claim that Cartalax rebuilds human cartilage.
Identity and formulation
AED is a three-amino-acid sequence. It should not be confused with AEDG, a different four-amino-acid peptide, or EDL, another peptide included in some of the same experiments.
A study comparing several peptides must assign each finding to the correct group. A stronger result for a kidney extract or EDL cannot be relabeled as a Cartalax result.
What the studies show
There is specific preclinical evidence worth describing, but its focus differs from common joint marketing. A sequence-based identity link allows the AED/T-31 studies to be considered cautiously. It does not turn kidney findings into clinical cartilage evidence.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals.
Organotypic kidney-tissue cultures from young and old rats Reading scope: PubMed abstract and bibliographic record; not full-text review |
T-31/AED and T-35/EDL affected proliferation and apoptosis-related measures, with smaller effects than the kidney-derived polypeptide complex. | The model concerned kidney tissue; the stronger extract result is not the isolated AED result. |
| Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure.
Rats with cisplatin-induced acute renal failure Reading scope: PubMed abstract and bibliographic record; not full-text review |
AED reduced urine protein excretion and electrolyte concentrations in the reported experiment. | Other peptides showed different and broader changes. This was an induced animal kidney-injury model, not a joint or human renal trial. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
The organ named in a product nickname is not a substitute for an experimental outcome. A cartilage claim should identify a cartilage model or a clinical joint endpoint involving the same peptide.
A lower urinary marker in a controlled animal experiment is preliminary evidence. It does not demonstrate prevention of human kidney disease, improved joint function or a broadly protective anti-aging effect.
Safety context
The selected studies do not establish human safety or a long-term risk profile. Findings in an induced kidney-injury model should not be interpreted as permission to expose people with kidney disease to an unverified material.
An apoptosis-related mechanism also does not independently settle benefits or harms in other tissues.
Study exposure and units
Keep AED, EDL, AEDG and kidney-extract exposures separate. A concentration for a comparator cannot become the Cartalax concentration.
Culture concentrations and animal exposures are research methods, not personal cartilage or kidney treatment schedules. No validated personal regimen follows from these sources.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Verify the ordered Ala–Glu–Asp sequence, termini and chemical form. Check that the report does not describe AEDG or a mixed organ extract instead.
A mass/purity document can support a sample identity question; it cannot establish cartilage regeneration or explain away a mismatched clinical citation.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Are there genuine primary papers behind the Cartalax name?
There are identifiable AED/T-31 studies and an NLM terminology mapping. The studies reviewed here are kidney-focused preclinical experiments, which is narrower than a claim of proven joint repair.
Can a study of AEDG support an AED claim?
Not without a justified direct comparison. Adding an amino acid creates a different peptide, and the studies themselves report group-specific results.
Sources
- Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. (PubMed abstract and bibliographic record; not full-text review)
- Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. (PubMed abstract and bibliographic record; not full-text review)
- NLM MeSH supplementary concept C572340 (Official terminology record and entry terms)